文章：

深入分析以明确免疫检查点抑制剂在非HER2阳性/HER2阴性晚期或转移性胃癌及胃食管结合部癌一线治疗中的真实获益

Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)

原文发布日期：15 February 2025

DOI: 10.3390/cancers17040657

类型: Article

开放获取: 是

英文摘要：

Gastric cancer (GC) has a high global incidence and mortality rate [...]

摘要翻译： 

胃癌在全球范围内具有较高的发病率和死亡率[...]

原文链接：

Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)